Scholar Rock SRRK
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Scholar Rock (SRRK) Business Model and Operations Summary
Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions.
Key Insights
Scholar Rock (SRRK) Core Market Data and Business Metrics
Latest Closing Price
$30.06Market Cap
$2.88 BillionPrice-Earnings Ratio
-12.74Total Outstanding Shares
94.68 Million SharesTotal Employees
196Dividend
No dividendIPO Date
May 24, 2018SIC Description
Biological Products, (no Disgnostic Substances)Primary Exchange
NASDAQHeadquarters
301 Binney Street, Cambridge, MA, 02142
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Operating Activities, Continuing | $-188.78 Million |
| Net Cash Flow From Financing Activities | $103.19 Million |
| Net Cash Flow From Investing Activities, Continuing | $94.19 Million |
| Net Cash Flow From Investing Activities | $94.19 Million |
| Net Cash Flow From Financing Activities, Continuing | $103.19 Million |
| Net Cash Flow, Continuing | $8.59 Million |
Income Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Operating Expenses | $230.73 Million |
| Research and Development | $169.15 Million |
| Depreciation and Amortization | $2.21 Million |
| Preferred Stock Dividends And Other Adjustments | $0 |
| Basic Average Shares | $99.82 Million |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0 |
Comprehensive Income
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Other Comprehensive Income/Loss | $151,000 |
| Other Comprehensive Income/Loss Attributable To Parent | $151,000 |
| Comprehensive Income/Loss | $-225.81 Million |
| Comprehensive Income/Loss Attributable To Parent | $-225.81 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
Balance Sheet
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Current Assets | $152.93 Million |
| Wages | $9.97 Million |
| Noncurrent Liabilities | $60.56 Million |
| Fixed Assets | $3.16 Million |
| Current Liabilities | $39.37 Million |
| Noncurrent Assets | $26.21 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||